Table 1. Main characteristics and results of the included studies.
| Author, Year, Country | Size | Age | Tumor type | Antibody and dilution | Intratumoral LVD and detection rate | Peritumoral LVD and detection rate |
|---|---|---|---|---|---|---|
| Doric, 2014, Bosnia and Herzegovina14 | 75 | 59 (37–87)a | invasive BC | D2–40 (1:100) | 1.9 ± 1.7 (27/75) | 3.9 ± 1.0 (75/75) |
| Raica, 2013, Italy15 | 55 | 26–81b | ductal invasive BC | D2–40 (NG) | 1.89 ± 2.35 (NG) | 6.85 ± 3.55 (NG) |
| Ciobanu, 2013, Romania16 | 25 | 58 (45–69)c | lobular invasive BC | D2–40 (1:100) | 3.40 ± 2.55 (18/25) | 8.68 ± 5.64 (19/25) |
| Zhao, 2012, China12 | 73 | 53.8 (29–75)a | ductal invasive BC | D2–40 (1:25) | 5.47 ± 2.03 (NG) | 8.77 ± 3.30 (NG) |
| Kandemir, 2012, Turkey17 | 69 | 54.8 (39–85)a | ductal invasive BC | D2–40 (1:50) | 16.3 ± 9.7 (18/69) | 66.3 ± 20.5 (25/69) |
| Ding, 2012, China18 | 75 | 52.1 (42–63)a | ductal invasive BC and Paget disease | D2–40 (NG) | 2.06 ± 2.93 (NG) | 12.99 ± 7.97 (NG) |
| Mohammed, 2009, UK11 | 177 | 57 (32–70)c | invasive BC | D2–40 (1:100) | 0.26 ± 0.51 (73/177) | 1.02 ± 0.76 (177/177) |
| Liu, 2009, China19 | 91 | NG | invasive BC | D2–40 (1:100) | 5.12 ± 2.69 (NG) | 8.22 ± 3.21 (NG) |
| EI-Gohary, 2008, USA10 | 48 | 64 (27–89)a | invasive BC | D2–40 (1:50) | 3.7 ± 6.1 (24/48) | 8.8 ± 6.8 (46/48) |
| Van der Schaft, 2007, Netherlands13 | 121 | 61.4 ± 12.2d | ductal invasive BC | Podoplanin (NG) | 0.35 ± 1.29 (12/121) | 4.68 ± 3.98 (55/121) |
| Li, 2006, Japan20 | 80 | NG | ductal invasive BC | D2–40 (1:100) | 1.93 ± 0.43 (NG) | 5.41 ± 0.85 (NG) |
| Agarwal, 2005, USA22 | 55 | 53 (35–72)a | invasive BC | D2–40 (1:40) | 0.3 ± 0.5 (NG) | 2.31 ± 0.97 (NG) |
| Van der Auwera, 2005, Belgium21 | 85 | 25.6–83.2b | inflammatory and non-inflammatory BC | D2–40 (1:20) | 5,24 ± 4.90 (68/84) | 8.25 ± 5.72 (NG) |
Note: a: mean (range); b: range; c: median (range); d: mean ± SD; BC: breast cancer; LVD: lymphatic vessel density; NG: not given.